NeuroPace Stock Plunges 34% After Mixed Results From Epilepsy Study

(RTTNews) - NeuroPace, Inc. (NPCE) shares dropped 33.7 percent to $11.73 on Tuesday, falling $5.95 after the company announced mixed one-year results from its NAUTILUS study evaluating the RNS System for drug-resistant idiopathic generalized epilepsy.

NPCE opened at $13.37 and traded between $10.63 and $14.75 during the session on the Nasdaq. Volume surged to 648,450 shares, well above the average of 246,673. The stock closed at $17.68 in the previous session.

Over the past 52 weeks, NeuroPace has traded between $5.45 and $18.98.

While the study met its 12-week post-implant safety endpoint with a low rate of serious adverse events, it failed to reach statistical significance for the primary effectiveness endpoint in the overall population.